MediciNova
MediciNova reported revenue of $0 million in fiscal 2025. Its operating margin was −3,242.5%. Free cash flow was −$10 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
MediciNova lost money in fiscal 2025: a net loss of $12 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 71 | 58 | — | 40 | 31 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 25.4x | 18.5x | 15.6x | 13.9x | 8.2x |
| Quick ratio | 25.4x | 18.5x | 15.6x | 13.9x | 8.2x |
Cash flow
Projections
Project MediciNova's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought MediciNova shares on the open market, and 1 insider sold $1.7 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | 3D Opportunity Master FundFormerly 10% Owner | Sold | 640,000 | $2.70 | $1.7 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | 0.12 | −5.60 | −18.54 |
| Accruals ratio | −1.6% | −0.7% | −4.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Pass | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — | — | — |
Compare
Put MediciNova side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| MediciNova | FY25 | — | −3,242.5% | −2,395.4% | — | — | — | |
| Scienture | FY25 | 215.9% | −9,867.9% | — | — | — | — | Compare |
| Mereo BioPharma Group | FY25 | — | −8,021.4% | −6,198.2% | — | — | 4 | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Allarity Therapeutics | FY25 | — | −3,939.1% | −4,633.8% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | 4 | — | 1 | — | 0 |
| Revenue growth | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 5 | 7 | 7 |
| Operating income | −11 | −13 | −16 | −14 | −14 | −10 | −15 | −10 | −13 | −13 |
| Net income | −11 | −11 | −15 | −13 | −14 | −10 | −14 | −9 | −11 | −12 |
| Diluted EPS (US$) | −0.33 | −0.32 | −0.36 | −0.30 | −0.31 | −0.21 | −0.29 | −0.17 | −0.23 | −0.24 |
| Diluted shares (millions) | 33 | 35 | 41 | 43 | 44 | 49 | 49 | 49 | 49 | 49 |
| Cash flow | ||||||||||
| Cash from operations | −6 | −7 | −9 | −9 | −11 | −9 | −13 | −7 | −11 | −10 |
| Capital expenditure | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −7 | — | −9 | −9 | −11 | −9 | −13 | −7 | −11 | −10 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 4 | 4 | 6 | 4 | 3 | 2 | 1 | 1 | 1 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 24 | 28 | 62 | 64 | 60 | 71 | 58 | — | 40 | 31 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 40 | 43 | 77 | 79 | 75 | 87 | 74 | 66 | 56 | 46 |
| Total liabilities | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 4 |
| Shareholders' equity | 34 | 39 | 73 | 75 | 71 | 84 | 70 | 62 | 52 | 42 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −253.0% | — | −990.0% | — | −3,242.5% |
| Net margin | — | — | — | — | — | −251.0% | — | −857.1% | — | −2,928.8% |
| Free cash flow margin | — | — | — | — | — | −233.1% | — | −745.2% | — | −2,395.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −32.3% | −30.5% | −26.3% | −17.5% | −18.9% | −13.1% | −18.3% | −12.9% | −19.2% | −25.5% |
| Return on assets | −28.0% | −26.8% | −24.3% | −16.6% | −17.9% | −12.4% | −17.4% | −12.2% | −18.1% | −23.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |